The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for ...

Katie and Lyndsay Cooper regularly monitored their breasts since discovering they had the BRCA1 mutation. Eventually, the ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

"Inside Edition" correspondent Alison Hall opens up about her breast cancer battle and how Olivia Munn's own experience with early detection inspired her to take a life-saving risk assessment test.

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Novel research has shown that women are frequently denied MRI scans, despite usual recommendations. Read more.

Scientists have analyzed thousands of mutations in the BRCA2 cancer gene, offering crucial insights. This research could help mitigate patient concerns or guide tailored treatments. By utilizing ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.